Lipocine Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/21/2021 12:44 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume21,898 shs
Average Volume3.25 million shs
Market Capitalization$120.08 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LPCN News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

Lipocine logo

About Lipocine

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.39 out of 5 stars

Medical Sector

748th out of 2,101 stocks

Pharmaceutical Preparations Industry

372nd out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Lipocine (NASDAQ:LPCN) Frequently Asked Questions

Is Lipocine a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lipocine stock.
View analyst ratings for Lipocine
or view top-rated stocks.

What stocks does MarketBeat like better than Lipocine?

Wall Street analysts have given Lipocine a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lipocine wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Lipocine?

Lipocine saw a decline in short interest in May. As of May 28th, there was short interest totaling 2,690,000 shares, a decline of 14.1% from the May 13th total of 3,130,000 shares. Based on an average daily volume of 2,130,000 shares, the days-to-cover ratio is currently 1.3 days. Currently, 3.1% of the company's shares are sold short.
View Lipocine's Short Interest

When is Lipocine's next earnings date?

Lipocine is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Lipocine

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) posted its earnings results on Thursday, May, 6th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01.
View Lipocine's earnings history

How has Lipocine's stock price been impacted by COVID-19?

Lipocine's stock was trading at $0.4511 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LPCN shares have increased by 201.5% and is now trading at $1.36.
View which stocks have been most impacted by COVID-19

What price target have analysts set for LPCN?

2 brokerages have issued 1-year target prices for Lipocine's stock. Their forecasts range from $2.50 to $3.00. On average, they anticipate Lipocine's share price to reach $2.75 in the next twelve months. This suggests a possible upside of 102.2% from the stock's current price.
View analysts' price targets for Lipocine
or view top-rated stocks among Wall Street analysts.

Who are Lipocine's key executives?

Lipocine's management team includes the following people:
  • Dr. Mahesh V. Patel, Co-Founder, Chairman, Pres & CEO (Age 64, Pay $780.14k)
  • Mr. Morgan R. Brown CPA, M.B.A., CPA, MBA, Exec. VP, CFO, Principal Accounting Officer & Corp. Sec. (Age 53, Pay $526.85k)
  • Mr. Nachiappan Chidambaram Ph.D., VP of Product Devel. (Age 52, Pay $344.35k)
  • Mr. Logan Morse, VP of Sales, Marketing & Operations (Age 51)
  • Dr. Anthony DelConte M.D., M. D., Chief Medical Director (Age 63)

Who are some of Lipocine's key competitors?

What other stocks do shareholders of Lipocine own?

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Who are Lipocine's major shareholders?

Lipocine's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Ameriprise Financial Inc. (0.80%), Geode Capital Management LLC (0.68%), Mercer Global Advisors Inc. ADV (0.24%), Virtu Financial LLC (0.22%), Northern Trust Corp (0.17%) and GSA Capital Partners LLP (0.14%). Company insiders that own Lipocine stock include John W Higuchi, Mahesh V Patel and Morgan R Brown.
View institutional ownership trends for Lipocine

Which institutional investors are selling Lipocine stock?

LPCN stock was sold by a variety of institutional investors in the last quarter, including Mercer Global Advisors Inc. ADV, GSA Capital Partners LLP, Ameriprise Financial Inc., and Virtu Financial LLC. Company insiders that have sold Lipocine company stock in the last year include John W Higuchi, Mahesh V Patel, and Morgan R Brown.
View insider buying and selling activity for Lipocine
or view top insider-selling stocks.

Which institutional investors are buying Lipocine stock?

LPCN stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Price T Rowe Associates Inc. MD, Squarepoint Ops LLC, Cubist Systematic Strategies LLC, MML Investors Services LLC, XTX Topco Ltd, Jane Street Group LLC, and Northern Trust Corp. Company insiders that have bought Lipocine stock in the last two years include John W Higuchi, and Mahesh V Patel.
View insider buying and selling activity for Lipocine
or or view top insider-buying stocks.

How do I buy shares of Lipocine?

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $1.36.

How much money does Lipocine make?

Lipocine has a market capitalization of $120.08 million and generates $170,000.00 in revenue each year. The specialty pharmaceutical company earns $-20,960,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does Lipocine have?

Lipocine employs 13 workers across the globe.

What is Lipocine's official website?

The official website for Lipocine is

Where are Lipocine's headquarters?

Lipocine is headquartered at 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]

This page was last updated on 6/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.